Bleeding Disorders
Conference Coverage
Fitusiran: Great ‘leap forward’ in hemophilia treatment
Cost will be a major consideration if fitusiran is approved for the U.S. market.
News
FDA approves new interferon for polycythemia vera
A longer half-life means dosing every 2 weeks, instead of weekly.
From the Journals
Data from Spain yield new insights on a rare hemophilia
Findings show high rates of antithrombotic use before diagnosis and fatal infections after immunosuppressive therapy starts.
From the Journals
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
From the Journals
No added risk of hepatic cancer in patients with hemophilia after successful HCV treatment
“Careful observation is needed in patients with hemophilia even after eradication of HCV.”
From the Journals
Intracranial hemorrhaging a high risk for patients with hemophilia, especially neonates
From the Journals
New gene variant found for hereditary bleeding disorder
From the Journals
Infusion shown effective for acquired von Willebrand disease
From the Journals
Recombinant factor IX fusion protein benefited untreated patients with hemophilia B
Recombinant factor IX Fc fusion protein (rFIXFc) was effective, both as prophylaxis and in the treatment of bleeding episodes in previously...
From the Journals
Bleeding events tied to higher mortality in patients with factor V inhibition
Conference Coverage
Novel molecule prolongs half-life of bleeding disorder treatments